Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will announce its financial results for Q1 2020 after market close on May 7, 2020. A conference call and webcast to discuss the results will be held at 4:30 PM ET on the same day. The company focuses on developing mRNA therapeutics for rare diseases and vaccines, with a robust pipeline that includes candidates for conditions such as Ornithine Transcarbamylase Deficiency, Cystic Fibrosis, and a self-replicating mRNA vaccine for SARS-CoV-2.

Positive

• Diverse pipeline targeting multiple rare diseases and vaccines, indicating potential for revenue generation.
• Established collaborations with major pharmaceutical companies, enhancing development capabilities.

Negative

• None.

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will release its financial results for the quarter ended March 31, 2020 after the market close on May 7 and will also provide a corporate overview and financial results by hosting a conference call and webcast at 4:30 pm Eastern Time on Thursday, May 7, 2020.

100%; border-collapse:collapse !important;">

Thursday, May 7th @ 4:30 pm ET
30%; width:30%; min-width:30%;">Domestic:	70%; width:70%; min-width:70%;">(833) 423-0426
International:	(918) 922-3070
Conference ID:	3273629
Webcast:	https://edge.media-server.com/mmc/p/xy5ogcuv

About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic candidates includes programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (187 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com

Contact
Neda Safarzadeh
Arcturus Therapeutics
(858) 900-2682
IR@ArcturusRx.com

Carlo Tanzi, Ph.D.
Kendall Investor Relations
(617) 914-0008 
ctanzi@kendallir.com

FAQ

When will Arcturus Therapeutics release its financial results?

Arcturus Therapeutics will release its financial results for the quarter ended March 31, 2020, on May 7, 2020.

What is the focus of Arcturus Therapeutics?

Arcturus Therapeutics focuses on the discovery, development, and commercialization of mRNA therapeutics for rare diseases and vaccines.

What time is the Arcturus Therapeutics conference call?

The conference call for discussing Arcturus Therapeutics' financial results is scheduled for May 7, 2020, at 4:30 PM ET.

What therapeutic areas does Arcturus Therapeutics target?

Arcturus Therapeutics targets rare diseases, including Ornithine Transcarbamylase Deficiency and Cystic Fibrosis, as well as vaccines.